In Today’s Issue:

• S&P 500 back above the 200 day moving average

• Overview of Trump’s “Most Favored Nation” Drug‐Pricing Order

• and more……..

Next Webinar:

Identifying and Profiting From the Top Themes in the Market

5/22 2pm EST

S&P 500 Back Above the 200 Day Moving Average

As expected, SPY closed above the 200 day moving average yesterday. This changes the complexion as the market is in a clear up trend and there are a number of market participants who use the 200 day as a trigger….

Not saying this is over by any means, I still think we have a number of twists and turns, but Greg sums it up perfectly…

Good active management thrives, which is hard to find, most active managers are index huggers…..

As evidenced by….

Wall Street research continues to be mostly useless….

Today’s big event is CPI….

The next big shoe to drop for bulls would be for the FOMC to start aggressively cutting rates, which they won’t do if they sniff inflation, so this could be an important number.

I continue to slowly add back into all of the top themes. Crypto related is a major one…

This is an example as COIN replaces and old line financial in the S&P 500…..

Also trying to find under the radar crypto related companies, here are three possibilities, all high risk. I own CYFRF but would probably have the other two (very small size) if I wasn’t golfing all day yesterday….

Another high risk theme I like is quantum computing. RGTI had earnings last night and is trading down big pre market…..

I asked GPT if it was a buy, sell, or hold based on this report….

Buy / Sell / Hold Recommendation

Hold.

• Why not Sell? The post-earnings drop has priced in the revenue miss and extended burn; a funded runway and recurring government milestones warrant staying in for the long-run quantum upside.

• Why not Buy? There’s no near-term inflection for commercial revenues. It remains a binary, R&D-milestone story—better suited for a satellite allocation in a high-beta quantum bucket, not a core position.

Bottom Line: RGTI is not broken, but it’s not yet “built.” Steer clear of adding new capital until you see consistent revenue growth or clear guidance on commercialization timelines.

Can’t wait for this…..

Overview of Trump’s “Most Favored Nation” Drug‐Pricing Order

On May 12, 2025, President Trump signed an executive order instructing HHS, the U.S. Trade Representative, Commerce and DOJ/FTC to pursue a “most favored nation” (MFN) policy—tying U.S. drug prices (across Medicare, Medicaid and the commercial market) to the lowest prices paid in other developed nations. The order demands that within 30 days HHS set price‐reduction targets with manufacturers; if unmet after six months, MFN pricing could be imposed by rulemaking or “other aggressive measures” AP News.

Short‐Term Impact

• Market reaction: Pharma stocks initially dipped on headline risk, then mostly rebounded as investors judged enforcement unlikely without Congress’s backing Investor's Business Daily.

• Uncertainty premium: With no drug list or country roster disclosed, near‐term volatility will persist—particularly around high‐expenditure classes like GLP-1s (e.g., Ozempic, Wegovy) and oncology drugs The Guardian.

Long‐Term Implications

• Margin compression: If enforced, linking U.S. prices to much lower international benchmarks (often 50–70% below U.S. levels) could shave $50–100 billion annually off Big Pharma’s U.S. revenues The Guardian.

• R&D headwinds: Trade‐group PhRMA warns that forced price cuts could reduce innovation budgets, potentially delaying or derailing late‐stage pipelines AP News.

• Supply‐chain reshoring: To curry regulatory or tariff relief, companies may accelerate U.S. on‐shore API and finished-dose manufacturing—benefiting domestic CMOs and engineering partners.

Potential Winners

Potential Losers

Bottom Line:
Trump’s MFN order ramps up the odds of a structural reset in U.S. drug pricing—good for lower-cost generics and domestic manufacturing plays, painful for high-margin biologics and blockbusters. Short term, expect choppy trading; longer‐term, the winners will be companies whose core business thrives at lower price points (TEVA, MYL, Vertex), while legacy branded drugmakers (LLY, PFE, MRK, BMY, AMGN) face genuine margin risk and should be rated conservatively unless explicit carve-outs emerge.

Before you go: Here are ways I can help

‍

1. ETFs: We offer innovative ETFs that cover all aspects of The H.E.A.T. Formula, Hedges, Edges, and Themes.

2. Consulting: I'm happy to jump on the phone with financial advisors at no charge. I've built a wealth management firm and helped other advisors grow their practices through the use of substantially differentiated investment strategies. If you want to talk just send me an email at [email protected]

3. Monthly investing webinars

4. Rebel Finance Podcast https://www.youtube.com/@TuttleCap

5. Wealth Management-Coming Soon

6. Paid Newsletter Service-Coming Soon

   The views and opinions expressed herein are those of the Chief Executive Officer and Portfolio Manager for Tuttle Capital Management (TCM) and are subject to change without notice. The data and information provided is derived from sources deemed to be reliable but we cannot guarantee its accuracy. Investing in securities is subject to risk including the possible loss of principal. Trade notifications are for informational purposes only. TCM offers fully transparent ETFs and provides trade information for all actively managed ETFs. TCM's statements are not an endorsement of any company or a recommendation to buy, sell or hold any security. Trade notification files are not provided until full trade execution at the end of a trading day. The time stamp of the email is the time of file upload and not necessarily the exact time of the trades. TCM is not a commodity trading advisor and content provided regarding commodity interests is for informational purposes only and should not be construed as a recommendation. Investment recommendations for any securities or product may be made only after a comprehensive suitability review of the investor’s financial situation.© 2025 Tuttle Capital Management, LLC (TCM). TCM is a SEC-Registered Investment Adviser. All rights reserved.